General Foreign Trade Organization Pharmaceutical Import Profile — Syria (DGFT 2022–2026)

Name: General Foreign Trade Organization Pharmaceutical Import Records from India — 3 Products, $252.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

General Foreign Trade Organization — Pharmaceutical Importer Profile (2026) | 3 Products, $252.2K Trade | TransData Nexus

General Foreign Trade Organization

Pharmaceutical Importer · Syria · Advanced Oncology Focus · $252.2K Total Trade · DGFT Verified

General Foreign Trade Organization is a pharmaceutical importer based in Syria with a total trade value of $252.2K across 3 products in 1 therapeutic categories. Based on 11 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. General Foreign Trade Organization sources from 4 verified Indian suppliers, with Vhb Medi Sciences Limited accounting for 34.7% of imports.

General Foreign Trade Organization — Import Portfolio & Supplier Network

General Foreign Trade Organization import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to General Foreign Trade Organization?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vhb Medi Sciences Limited	$304.5K	13	34.7%
Reliance Life Sciences Private Limited	$300.0K	16	34.2%
Khandelwal Laboratories Private Limited

What Formulations Does General Foreign Trade Organization Import?

Formulation	Value	Ships
Trasturel 440MG trastuzumab 440 MG	$100.0K	2
Bleonbleomycin for injection USP 15 unitspack:vialpharmaceutical	$84.6K	4
Temozol 100mgtemozolamide 100 MG cappack: 5 CAPS in a	$62.1K	4
Alburel 20% 50 ML 17908 vials of human	$50.0K	1
Immunorel 5% 50ML 4650 vials of human	$50.0K	1
Alburel 20% 50 ML 33086 vials of human	$50.0K	1
Piperacillin & tazobactum for	$50.0K	1
Trasturel 440MG trastuzumab 440 MG	$50.0K	1
Methylprednisolone sodium succinate	$49.3K	2
Doxorubicin for infusion BP 50 MG adrosal	$33.8K	1
Gemcitabine for injection USP 200MG	$33.4K	1
Cytarabine injection BP 1000MG/10 ML	$24.8K	1
Oxaliplatin injection USP 100 MG 50 ML	$22.7K	1
Cefoperazone and sulbactam for	$22.4K	1
Xalipat 100 MG (oxaliplatin INJ 100 MG)packing	$19.0K	2

General Foreign Trade Organization imports 62 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Trastuzumab	Advanced Oncology	$150.0K	3	0.2%	9
2	Bleomycin	Advanced Oncology	$84.6K	6	1.5%	10
3	Dacarbazine	Advanced Oncology	$17.6K	2	1.2%	11

General Foreign Trade Organization imports 3 pharmaceutical products across 1 categories into Syria totaling $252.2K.

General Foreign Trade Organization — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The General Foreign Trade Organization (GFTO) is a Syrian state-owned entity responsible for overseeing and regulating the import and export of goods, including pharmaceuticals, within Syria. As a government procurement agency, GFTO plays a pivotal role in ensuring the availability of essential medicines and medical supplies to meet the country's healthcare needs. Headquartered in Damascus, Syria, GFTO operates under the Ministry of Economy and Foreign Trade, coordinating with various governmental bodies to facilitate international trade and maintain compliance with national regulations.

In the pharmaceutical sector, GFTO acts as a primary importer, sourcing finished pharmaceutical formulations from international suppliers to supplement domestic production. This strategy is particularly crucial given the challenges faced by Syria's local pharmaceutical industry, which has experienced significant setbacks due to ongoing conflicts and economic sanctions. By importing finished products, GFTO ensures a continuous supply of essential medications, thereby supporting the healthcare infrastructure and addressing the therapeutic needs of the Syrian population.

2Distribution Network

GFTO's distribution network is strategically designed to ensure the efficient delivery of pharmaceutical products across Syria. While specific warehouse locations are not publicly disclosed, the organization collaborates with local distributors and logistics partners to facilitate nationwide coverage. This network is essential for maintaining the timely availability of imported medicines, especially in regions where local production is insufficient or non-existent.

The logistics capabilities of GFTO are tailored to navigate the complexities of Syria's infrastructure, which has been affected by years of conflict. The organization employs a combination of road, rail, and, where feasible, air transport to distribute pharmaceuticals efficiently. Additionally, GFTO's partnerships with neighboring countries, such as Jordan and Turkey, enhance its ability to import and distribute medicines, leveraging regional trade routes and facilities to bolster supply chain resilience.

3Industry Role

In Syria's pharmaceutical supply chain, GFTO serves as a primary wholesaler and government procurement agency. By importing finished pharmaceutical formulations, GFTO supplements domestic production, ensuring the availability of essential medicines that may not be produced locally. This role is particularly critical given the challenges faced by Syria's local pharmaceutical industry, which has experienced significant setbacks due to ongoing conflicts and economic sanctions. Through its import activities, GFTO plays a vital role in maintaining the stability and accessibility of the country's healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — General Foreign Trade Organization

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

GFTO's sourcing strategy reveals a high degree of concentration, with a total import value of $252,000 USD from India across 11 shipments, encompassing three products within the Advanced Oncology therapeutic category. The top three products imported are Trastuzumab ($150,000 USD), Bleomycin ($85,000 USD), and Dacarbazine ($18,000 USD), collectively accounting for 100% of the import portfolio. This concentration indicates a strategic focus on specific oncology treatments, likely driven by the pressing demand for cancer therapies in Syria.

The reliance on a limited number of products and suppliers suggests a potential risk in supply chain stability. Any disruptions affecting these key products or suppliers could significantly impact GFTO's ability to meet the country's oncology treatment needs. However, this focused sourcing approach may also reflect a strategic decision to concentrate resources on high-demand, high-impact medications, optimizing procurement efficiency and cost-effectiveness.

2Supply Chain Resilience

GFTO's supply chain resilience is closely tied to its sourcing strategy from India. The organization imports finished pharmaceutical formulations, including Trastuzumab, Bleomycin, and Dacarbazine, from four verified Indian suppliers: VHB Medi Sciences Limited, Reliance Life Sciences Private Limited, Khandelwal Laboratories Private Limited, and VHB Medisciences Limited. The substantial number of shipments from Khandelwal Laboratories Private Limited (59 shipments) indicates a strong and possibly exclusive relationship, which could be advantageous in terms of pricing and supply reliability.

Importing Pharmaceuticals into Syria — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Syria

1Regulatory Authority & Framework

In Syria, the Ministry of Health (MoH) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The Directorate of Pharmaceutical Affairs, a division within the MoH, is responsible for registering pharmaceutical products, issuing import licenses, and ensuring compliance with national standards. This includes the requirement for a Certificate of Pharmaceutical Products (COPP), which verifies that a pharmaceutical product is authorized for sale in the country of origin and manufactured in compliance with recognized regulatory standards.

The regulatory framework governing pharmaceutical imports in Syria is designed to ensure that imported medicines meet the necessary safety, efficacy, and quality standards. Importers must obtain approval from the MoH, submit required documentation, and adhere to established procedures to facilitate the importation process. This regulatory oversight is crucial for maintaining the integrity of the pharmaceutical supply chain and safeguarding public health.

2Import Licensing & GMP

Import licensing in Syria is a mandatory process for pharmaceutical products, ensuring that imported medicines comply with national standards. The Ministry of Health requires importers to obtain approval, submit necessary documentation, and adhere to established procedures to facilitate the importation process. This process includes the submission of a Certificate of Pharmaceutical Products (COPP), which verifies that a pharmaceutical product is authorized for sale in the country of origin and manufactured in compliance with recognized regulatory standards.

General Foreign Trade Organization — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

GFTO's product strategy focuses on importing finished pharmaceutical formulations within the Advanced Oncology therapeutic category, specifically Trastuzumab, Bleomycin, and Dacarbazine. This focus is likely driven by the high demand for cancer treatments in Syria, where the local pharmaceutical industry may face challenges in meeting these needs due to infrastructure limitations and resource constraints. By importing these specific products, GFTO aims to ensure the availability of essential oncology medications, thereby supporting the healthcare system and addressing critical therapeutic gaps.

The decision to concentrate on these specific therapeutic areas reflects a strategic approach to procurement, aligning with the pressing healthcare needs of the Syrian population. This targeted strategy enables GFTO to streamline its import processes, negotiate favorable terms with suppliers, and maintain a steady supply of high-demand medications.

2Sourcing Profile

GFTO's sourcing strategy involves importing generic drug formulations from India, focusing on specific oncology treatments. The organization imports finished pharmaceutical formulations, including Trastuzumab, Bleomycin, and Dacarbazine, from four verified Indian suppliers: VHB Medi Sciences Limited,

TransData Nexus Research · DGFT trade data analysis

Frequently Asked Questions — General Foreign Trade Organization

What products does General Foreign Trade Organization import from India?

General Foreign Trade Organization imports 3 pharmaceutical products across 1 categories. Top imports: Trastuzumab ($150.0K), Bleomycin ($84.6K), Dacarbazine ($17.6K).

Who supplies pharmaceuticals to General Foreign Trade Organization from India?

General Foreign Trade Organization sources from 4 verified Indian suppliers. The primary supplier is Vhb Medi Sciences Limited (34.7% of imports, $304.5K).

What is General Foreign Trade Organization's total pharmaceutical import value?

General Foreign Trade Organization's total pharmaceutical import value from India is $252.2K, based on 11 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does General Foreign Trade Organization focus on?

General Foreign Trade Organization imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full General Foreign Trade Organization Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.